RxDoctor Payments Data

Ramalingeswara Nimmagadda

Internal Medicine · McLean, VANPI 1396773859

Payments from drug & device makers

$860in general payments, 2019–2025

Across 20 payments — averaging $43.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$228
  • Astellas Pharma US Inc$219
  • Amgen$99
  • Pfizer$91
  • Novo Nordisk$68
  • Boehringer Ingelheim$53
  • plus $102 from 4 others

What the payments were for

  • Food & beverage$63474%
  • Education$22626%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$860 in reported general payments places this provider in the 75th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$104,945
Medicare patients
235
Services billed
1,000

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban32$46,132
MyrbetriqMirabegron27$22,620
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$15,109
OzempicSemaglutide11$13,991
Galantamine ErGalantamine Hbr13$2,785
Rosuvastatin Calcium100$2,104
Silodosin13$1,946
SynthroidLevothyroxine Sodium17$1,938
Atorvastatin Calcium105$1,842
Levothyroxine Sodium110$1,638
Pantoprazole Sodium66$1,239
Telmisartan19$963
Losartan Potassium77$940
Irbesartan11$806
Amlodipine Besylate102$774

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$91$46,13232 claims
Astellas Pharma US IncMyrbetriq$219$22,62027 claims
Novo NordiskOzempic$68$13,99111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in McLean

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →